|
US3024257A
(en)
|
1961-04-10 |
1962-03-06 |
Frosst & Co Charles E |
Stable preparations of alkali metal salts of estrone sulfate
|
|
FR2340735A1
(fr)
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
|
IE52670B1
(en)
|
1981-03-03 |
1988-01-20 |
Leo Ab |
Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
|
|
DE3437232A1
(de)
|
1984-10-10 |
1986-04-17 |
Mack Chem Pharm |
Stabilisierte injektionsloesungen von piroxicam
|
|
US4782155A
(en)
|
1986-03-19 |
1988-11-01 |
Banyu Pharmaceutical Co., Ltd. |
Cephalosporin derivatives, processes for their preparation and antibacterial agents
|
|
US5139878A
(en)
|
1991-08-12 |
1992-08-18 |
Allied-Signal Inc. |
Multilayer film constructions
|
|
US5540934A
(en)
|
1994-06-22 |
1996-07-30 |
Touitou; Elka |
Compositions for applying active substances to or through the skin
|
|
US5912349A
(en)
|
1997-01-31 |
1999-06-15 |
Pharmacia & Upjohn Company |
Process for the preparation of roquinimex
|
|
US20030124187A1
(en)
|
1997-02-14 |
2003-07-03 |
Smithkline Beecham Laboratoires Pharmaceutiques, |
Pharmaceutical formulations comprising amoxycillin and clavulanate
|
|
US6696407B1
(en)
|
1997-03-21 |
2004-02-24 |
The Regents Of The University Of California |
Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
|
|
GB9726339D0
(en)
|
1997-12-13 |
1998-02-11 |
Zeneca Ltd |
Human-derived tissue-specific potassium channel
|
|
SE9801474D0
(sv)
|
1998-04-27 |
1998-04-27 |
Active Biotech Ab |
Quinoline Derivatives
|
|
US6077851A
(en)
|
1998-04-27 |
2000-06-20 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6133285A
(en)
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
|
US6121287A
(en)
|
1998-07-15 |
2000-09-19 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802549D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
SE9802550D0
(sv)
|
1998-07-15 |
1998-07-15 |
Active Biotech Ab |
Quinoline derivatives
|
|
PL199781B1
(pl)
|
1999-10-25 |
2008-10-31 |
Active Biotech Ab |
Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
|
|
WO2002007757A2
(en)
|
2000-07-21 |
2002-01-31 |
Lue Tom F |
Prevention and treatment of sexual arousal disorders
|
|
US6307050B1
(en)
|
2000-08-29 |
2001-10-23 |
R. T. Alamo Venture I Llc |
Method of synthesizing flosequinan from 4-fluoroanthranilic acid
|
|
US6802422B2
(en)
|
2000-12-12 |
2004-10-12 |
Multi-Comp, Inc. |
Sealed blister assembly
|
|
US6706733B2
(en)
|
2001-05-08 |
2004-03-16 |
Dainippon Ink And Chemicals, Inc. |
Quinolinone derivative formulation and its production method
|
|
US20030119826A1
(en)
|
2001-09-24 |
2003-06-26 |
Pharmacia Corporation |
Neuroprotective treatment methods using selective iNOS inhibitors
|
|
US6875869B2
(en)
|
2002-06-12 |
2005-04-05 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
US7560557B2
(en)
|
2002-06-12 |
2009-07-14 |
Active Biotech Ag |
Process for the manufacture of quinoline derivatives
|
|
SE0201778D0
(sv)
|
2002-06-12 |
2002-06-12 |
Active Biotech Ab |
Process for the manufacture of quinoline derivatives
|
|
ATE356808T1
(de)
|
2002-06-25 |
2007-04-15 |
Merck Frosst Canada Ltd |
8-(biaryl)chinolin-pde4-inhibitoren
|
|
US20070292461A1
(en)
|
2003-08-04 |
2007-12-20 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7820145B2
(en)
|
2003-08-04 |
2010-10-26 |
Foamix Ltd. |
Oleaginous pharmaceutical and cosmetic foam
|
|
US7790197B2
(en)
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
|
US20050271717A1
(en)
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
|
AU2004251750A1
(en)
|
2003-06-25 |
2005-01-06 |
Elan Pharmaceuticals, Inc. |
Methods and compositions for treating rheumatoid arthritis
|
|
US8795693B2
(en)
|
2003-08-04 |
2014-08-05 |
Foamix Ltd. |
Compositions with modulating agents
|
|
SE0400235D0
(sv)
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
|
US8314124B2
(en)
|
2004-02-06 |
2012-11-20 |
Active Biotech Ab |
Crystalline salts of quinoline compounds and methods for preparing them
|
|
JP2007531735A
(ja)
|
2004-04-01 |
2007-11-08 |
エラン ファーマシューティカルズ，インコーポレイテッド |
ステロイド節約剤および該節約剤を使用する方法
|
|
CA2579038A1
(en)
|
2004-09-02 |
2006-03-16 |
Teva Pharmaceutical Industries, Ltd. |
Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
|
|
DK1797109T3
(en)
|
2004-09-09 |
2016-04-11 |
Yeda Res & Dev |
MIXTURES OF POLYPEPTIDES, compositions containing them and methods for their preparation, and uses thereof
|
|
US20060205822A1
(en)
|
2004-12-22 |
2006-09-14 |
Forest Laboratories, Inc. |
1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
|
|
JP2008527002A
(ja)
|
2005-01-13 |
2008-07-24 |
サートリス ファーマシューティカルズ， インコーポレイテッド |
神経変性障害および血液凝固障害を予防および処置するための新規組成物
|
|
EP1902034B1
(en)
|
2005-06-02 |
2011-03-30 |
Glenmark Pharmaceuticals S.A. |
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
|
|
CA2626082C
(en)
|
2005-10-13 |
2017-04-11 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
SG10201508623RA
(en)
|
2005-10-19 |
2015-11-27 |
Teva Pharma |
Crystals of laquinimod sodium, and process for the manufacture thereof
|
|
RS52229B
(sr)
|
2005-10-26 |
2012-10-31 |
Merck Serono Sa. |
Derivati sulfonamida i njihova upotreba za modulaciju metaloproteinaza
|
|
US20080108641A1
(en)
|
2006-02-08 |
2008-05-08 |
Ajami Alfred M |
Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
|
|
US8367629B2
(en)
|
2006-02-14 |
2013-02-05 |
Noxxon Pharma Ag |
MCP-1 binding nucleic acids and use thereof
|
|
CA2641160A1
(en)
|
2006-02-28 |
2007-09-07 |
Elan Pharmaceuticals, Inc. |
Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
|
|
HUE047230T2
(hu)
*
|
2006-02-28 |
2020-04-28 |
Biogen Ma Inc |
Gyulladásos és autoimmun betegségek natalizumabbal való kezelésének módszerei
|
|
AU2007224228B2
(en)
|
2006-03-03 |
2013-09-19 |
Biogen Ma Inc. |
Methods of treating inflammatory and autoimmune diseases with natalizumab
|
|
WO2007109052A2
(en)
|
2006-03-16 |
2007-09-27 |
Genentech, Inc. |
Methods of treating lupus using cd4 antibodies
|
|
WO2007120656A2
(en)
|
2006-04-10 |
2007-10-25 |
Abbott Biotechnology Ltd. |
Uses and compositions for treatment of rheumatoid arthritis
|
|
WO2007146331A1
(en)
|
2006-06-12 |
2007-12-21 |
Teva Pharmaceutical Industries, Ltd. |
Tannate salt form of polypeptide mixtures, their preparation and use
|
|
KR20150065951A
(ko)
|
2006-06-12 |
2015-06-15 |
테바 파마슈티컬 인더스트리즈 리미티드 |
안정한 라퀴니모드 제제
|
|
RU2009105179A
(ru)
|
2006-07-17 |
2010-08-27 |
Новартис АГ (CH) |
Сульфониламинокарбонилпроизводные амидов холевой кислоты для применения в качестве иммуномодуляторов
|
|
EP1886996A1
(en)
|
2006-08-10 |
2008-02-13 |
Ferrer Internacional, S.A. |
1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
|
|
EP2056818B1
(en)
|
2006-08-11 |
2011-05-25 |
The Johns Hopkins University |
Compositions and methods for neuroprotection
|
|
WO2008021532A2
(en)
|
2006-08-17 |
2008-02-21 |
University Of Chicago |
Treatment of inflammatory diseases
|
|
WO2008085484A2
(en)
|
2006-12-28 |
2008-07-17 |
Jacobus Pharmaceutical Company, Inc. |
Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
|
|
PT2187882E
(pt)
|
2007-07-11 |
2013-04-17 |
Medicinova Inc |
Tratamento de uma doença neurodegenerativa progressiva com ibudilast
|
|
US20100260716A1
(en)
|
2007-10-23 |
2010-10-14 |
Ucb Pharma Gmbh |
Compounds for treating demyelination conditions
|
|
WO2009082471A1
(en)
|
2007-12-20 |
2009-07-02 |
Teva Pharmaceutical Industries, Ltd. |
Stable laquinimod preparations
|
|
ES2329327B1
(es)
|
2008-03-19 |
2010-09-17 |
Proyecto De Biomedicina Cima, S.L. |
Combinaciones sinergicas de 5'-metiltioadenosina.
|
|
MX2011002033A
(es)
|
2008-09-03 |
2011-05-02 |
Teva Pharma |
2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
|
EP2442651B1
(en)
|
2009-06-19 |
2015-07-29 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with laquinimod
|
|
ES2564931T3
(es)
|
2009-07-30 |
2016-03-30 |
Teva Pharmaceutical Industries Ltd. |
Tratamiento de enfermedad de Crohn con laquinimod
|
|
CA2771203C
(en)
|
2009-08-10 |
2019-04-09 |
Teva Pharmaceutical Industries Ltd. |
Treatment of bdnf-related disorders using laquinimod
|
|
DE102010026879A1
(de)
*
|
2010-02-11 |
2011-08-11 |
AMW GmbH, 83627 |
Transdermales System mit Immunmodulator
|
|
WO2011109526A1
(en)
|
2010-03-03 |
2011-09-09 |
Teva Pharmaceutical Industries Ltd. |
Treatment of lupus nephritis using laquinimod
|
|
US20110217295A1
(en)
|
2010-03-03 |
2011-09-08 |
Asi Haviv |
Treatment of lupus arthritis using laquinimod
|
|
MX2012010066A
(es)
|
2010-03-03 |
2012-10-03 |
Teva Pharma |
Tratamiento de artritis reumatoide con una combinacion de laquinimod y metotrexato.
|
|
CN104610144A
(zh)
|
2010-07-09 |
2015-05-13 |
泰华制药工业有限公司 |
氘化的n-乙基-n-苯基-1,2-二氢-4-羟基-5-氯-1-甲基-2-氧代喹啉-3-甲酰胺、其盐和用途
|
|
EA201390074A1
(ru)
|
2010-07-09 |
2013-06-28 |
Тева Фармасьютикал Индастриз Лтд. |
5-хлор-4-гидрокси-1-метил-2-оксо-n-фенил-1,2-дигидрохинолин-3-карбоксамид, его соли и применения
|
|
CA2820586A1
(en)
|
2010-12-07 |
2012-06-14 |
Teva Pharmaceutical Industries Ltd. |
Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
|
|
WO2012131539A1
(en)
|
2011-03-31 |
2012-10-04 |
Pfizer Inc. |
Novel bicyclic pyridinones
|
|
CN103781354A
(zh)
|
2011-07-28 |
2014-05-07 |
泰华制药工业有限公司 |
用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
|
|
SG10201606204TA
(en)
|
2011-07-28 |
2016-09-29 |
Teva Pharma |
Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta
|
|
EP2766020A4
(en)
|
2011-10-12 |
2015-04-01 |
Teva Pharma |
TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
|
|
MX2014009889A
(es)
|
2012-02-16 |
2014-11-13 |
Teva Pharma |
N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
|
|
US20130259856A1
(en)
|
2012-03-27 |
2013-10-03 |
Teva Pharmaceutical Industries, Ltd. |
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
|
|
AR090885A1
(es)
|
2012-05-02 |
2014-12-10 |
Teva Pharma |
Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
|
|
TW201350467A
(zh)
|
2012-05-08 |
2013-12-16 |
Teva Pharma |
Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
|
|
TW201400117A
(zh)
|
2012-06-05 |
2014-01-01 |
Teva Pharma |
使用拉喹莫德治療眼發炎疾病
|
|
WO2014004733A1
(en)
|
2012-06-26 |
2014-01-03 |
The Regents Of The University Of California |
Composition for lupus nephritis and methods of making and using the same
|
|
AR091706A1
(es)
|
2012-07-11 |
2015-02-25 |
Teva Pharma |
Formulaciones de laquinimod sin agentes alcalinizantes
|
|
UY34896A
(es)
|
2012-07-12 |
2014-02-28 |
Teva Pharma |
Tratamiento de la esclerosis múltiple con una combinación de laquinimod y fampridina
|
|
TW201410244A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
TW201410243A
(zh)
|
2012-08-13 |
2014-03-16 |
Teva Pharma |
用於治療大麻素受體型１（ｃｂ１）媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
|
|
US20140107154A1
(en)
|
2012-10-12 |
2014-04-17 |
Teva Pharmaceutical Industries, Ltd. |
Laquinimod for reducing thalamic damage in multiple sclerosis
|
|
MX2015005632A
(es)
|
2012-11-07 |
2016-02-05 |
Teva Pharma |
Sales de amina de laquinimod.
|
|
WO2014127139A1
(en)
|
2013-02-15 |
2014-08-21 |
Teva Pharmaceutical Industries Ltd. |
Treatment of multiple sclerosis with laquinimod
|
|
MX2015010967A
(es)
|
2013-03-14 |
2015-10-26 |
Teva Pharma |
Formulaciones transdermicas de laquinimod.
|
|
EP2970129A2
(en)
|
2013-03-14 |
2016-01-20 |
Teva Pharmaceutical Industries Ltd. |
Crystals of laquinimod sodium and improved process for the manufacture thereof
|
|
EP3094330A4
(en)
*
|
2014-01-17 |
2017-09-27 |
Teva Pharmaceutical Industries Ltd |
Treatment of crohn's disease using low doses of laquinimod
|